Core Viewpoint - West Pharmaceutical Services (WST) has shown a significant price increase of 11.1% over the past four weeks, with a mean price target of $316.82 indicating a potential upside of 28.7% from the current price of $246.2 [1] Price Targets and Analyst Consensus - The average price target for WST is based on 11 short-term estimates, ranging from a low of $260.00 to a high of $355.00, with a standard deviation of $34.23, suggesting variability in analyst predictions [2] - The lowest estimate indicates a 5.6% increase, while the highest suggests a 44.2% upside, highlighting the range of analyst expectations [2] - A low standard deviation among price targets indicates strong agreement among analysts regarding the stock's price movement direction [9] Earnings Estimates and Analyst Optimism - Analysts have shown increasing optimism about WST's earnings prospects, as evidenced by a trend of higher EPS estimate revisions, which correlates with potential stock price increases [11] - Over the last 30 days, four estimates for the current year have been revised upward, resulting in a 7.6% increase in the Zacks Consensus Estimate [12] - WST holds a Zacks Rank 1 (Strong Buy), placing it in the top 5% of over 4,000 ranked stocks based on earnings estimate factors, indicating strong potential for upside [13] Caution on Price Targets - While price targets are a common tool for investors, they can often mislead, as empirical research shows that they rarely indicate actual stock price movements [7] - Analysts may set overly optimistic price targets due to business incentives, which can inflate expectations [8] - Investors are advised to treat price targets with skepticism and not rely solely on them for investment decisions [10]

Group 1 - Harrow (HROW) shares have increased by 10.7% in the past four weeks, closing at $40.01, with a mean price target of $61.31 indicating a potential upside of 53.2% [1] - The mean estimate consists of seven short-term price targets with a standard deviation of $8.32, where the lowest estimate is $52.20 (30.5% increase) and the highest is $76.00 (90% increase) [2] - Analysts show strong agreement in revising earnings estimates higher, with the Zacks Consensus Estimate for the current year increasing by 39% over the past month [11][12] Group 2 - HROW holds a Zacks Rank 1 (Strong Buy), placing it in the top 5% of over 4,000 ranked stocks based on earnings estimates [13] - The clustering of price targets with a low standard deviation suggests a high degree of agreement among analysts regarding the stock's price movement [9] - While price targets can be misleading, the direction implied by them may serve as a useful guide for potential price movements [10][14]

Core Viewpoint - Passage Bio, Inc. (PASG) has seen a significant stock price increase of 31.5% over the past four weeks, closing at $7.59, with analysts suggesting a potential upside of 1415.2% based on a mean price target of $115 [1][2]. Price Targets and Analyst Estimates - The mean estimate of $115 is derived from four short-term price targets, with the lowest estimate at $40.00 indicating a 427% increase, while the highest target suggests a surge of 3325.6% to $260.00 [2]. - The standard deviation of $103.76 indicates variability among analysts' estimates, with a smaller standard deviation suggesting greater agreement [2][9]. Earnings Estimates and Analyst Agreement - Analysts show strong agreement in revising earnings estimates higher for PASG, which is a positive indicator for potential stock upside [4][11]. - The Zacks Consensus Estimate for the current year has increased by 8.7% over the past month, with no negative revisions, further supporting the optimistic outlook [12]. Zacks Rank and Investment Potential - PASG holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimate factors, indicating strong potential for near-term upside [13]. - While consensus price targets may not be entirely reliable, the direction they imply appears to be a useful guide for potential price movement [14].

Group 1 - The Beachbody Company, Inc. (BODI) shares have increased by 27.3% in the past four weeks, closing at $5.04, with a mean price target of $10.83 indicating a potential upside of 114.9% [1] - The average price targets range from a low of $4.00 to a high of $15.50, with a standard deviation of $6.05, suggesting variability in analyst estimates [2] - Analysts show a consensus that BODI will report better earnings than previously estimated, which historically correlates with stock price increases [4][11] Group 2 - The Zacks Consensus Estimate for BODI's current year earnings has risen by 49.1% over the past month, indicating positive sentiment among analysts [12] - BODI holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimate factors, suggesting strong potential for upside [13] - While consensus price targets may not be entirely reliable, the implied direction of price movement appears to be a useful guide for investors [14]

Core Viewpoint - Alvotech (ALVO) shares have increased by 2.9% recently, closing at $8.65, with a potential upside indicated by Wall Street analysts' price targets suggesting a mean estimate of $17.5, representing a 102.3% upside [1][2]. Price Targets and Analyst Estimates - The mean estimate consists of four short-term price targets with a standard deviation of $7, where the lowest estimate is $14.00 (61.9% increase) and the highest is $28.00 (223.7% increase) [2]. - A low standard deviation indicates a strong agreement among analysts regarding the price targets, suggesting a more reliable consensus [2][9]. Earnings Estimates and Analyst Sentiment - Analysts show strong agreement in revising earnings estimates higher, which correlates with potential stock price increases [4][11]. - Over the last 30 days, the Zacks Consensus Estimate for the current year has risen by 6.3%, with one estimate increasing and no negative revisions [12]. Zacks Rank and Investment Potential - ALVO holds a Zacks Rank 1 (Strong Buy), placing it in the top 5% of over 4,000 ranked stocks based on earnings estimates [13]. - While consensus price targets may not be entirely reliable, the direction they imply appears to be a good guide for potential price movement [14].

Core Viewpoint - KALA Bio (KALA) has shown a significant price increase of 35.9% over the past four weeks, with analysts projecting a mean price target of $13, indicating a potential upside of 74.7% from the current price of $7.44 [1][11]. Price Targets and Analyst Consensus - The average price target for KALA ranges from a low of $12.00 to a high of $15.00, with a standard deviation of $1.73, suggesting a relatively tight clustering of estimates among analysts [2][9]. - The lowest estimate indicates a potential increase of 61.3%, while the highest suggests a 101.6% upside [2]. - A low standard deviation indicates strong agreement among analysts regarding the stock's price movement direction, which can serve as a starting point for further research [9]. Earnings Estimates and Analyst Optimism - There is increasing optimism among analysts regarding KALA's earnings prospects, as evidenced by a positive trend in earnings estimate revisions [11]. - Over the last 30 days, one estimate has increased, leading to a 1.7% rise in the Zacks Consensus Estimate for the current year [12]. - KALA holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimates, indicating strong potential for upside [13]. Caution on Price Targets - While price targets are often sought after by investors, they can be misleading and should not be the sole basis for investment decisions [3][10]. - Analysts may set overly optimistic price targets due to business incentives, which can inflate expectations [8].

Group 1 - Potbelly (PBPB) shares have increased by 1.2% over the past four weeks, closing at $12.85, with a mean price target of $17.33 indicating a potential upside of 34.9% [1] - The mean estimate includes three short-term price targets with a standard deviation of $3.06, where the lowest estimate of $14.00 suggests a 9% increase, and the highest estimate of $20.00 indicates a 55.6% surge [2] - Analysts show strong agreement on PBPB's ability to report better earnings, with a positive trend in earnings estimate revisions correlating with potential stock price increases [4][11] Group 2 - The Zacks Consensus Estimate for PBPB has risen by 13% over the past month, with no negative revisions, indicating positive earnings prospects [12] - PBPB holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimates, suggesting a strong potential upside [13] - While consensus price targets may not be entirely reliable, the direction they imply appears to be a good guide for potential price movement [14]

Core Viewpoint - Embecta Corp. (EMBC) has shown a significant price increase of 22.8% over the past four weeks, with a mean price target of $16 indicating a potential upside of 25.7% from the current trading price of $12.73 [1] Price Targets and Estimates - The mean estimate consists of three short-term price targets with a standard deviation of $7.81, where the lowest estimate is $11.00 (indicating a 13.6% decline) and the highest estimate is $25.00 (indicating a 96.4% increase) [2] - A low standard deviation among price targets suggests a high degree of agreement among analysts regarding the stock's price movement [9] Analyst Sentiment and Earnings Estimates - Analysts are optimistic about EMBC's earnings prospects, as indicated by a positive trend in earnings estimate revisions, which has historically correlated with stock price movements [11] - Over the last 30 days, one earnings estimate has increased, leading to a 4.3% rise in the Zacks Consensus Estimate for the current year [12] Zacks Rank and Investment Potential - EMBC holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimate factors, indicating strong potential for upside in the near term [13]

Core Viewpoint - Carriage Services (CSV) shares have shown a 1.2% increase over the past four weeks, closing at $47.49, with analysts suggesting a potential upside of 27% based on a mean price target of $60.33 [1] Price Targets and Analyst Consensus - The average price target for CSV ranges from a low of $56.00 to a high of $65.00, with a standard deviation of $4.51, indicating a relatively tight clustering of estimates [2] - The lowest estimate suggests a 17.9% increase from the current price, while the highest estimate indicates a 36.9% upside [2] - A low standard deviation signifies strong agreement among analysts regarding the stock's price movement [9] Earnings Estimates and Market Sentiment - Analysts have shown strong agreement in revising earnings per share (EPS) estimates higher for CSV, which correlates with potential stock price increases [11] - The Zacks Consensus Estimate for the current year has risen by 3.3% over the past month, with two estimates increasing and no negative revisions [12] - CSV holds a Zacks Rank 1 (Strong Buy), placing it in the top 5% of over 4,000 ranked stocks based on earnings estimate factors, indicating strong potential for upside [13] Caution on Price Targets - While price targets are often sought after, they can mislead investors, and reliance solely on them may not yield favorable returns [3][10] - Analysts may set overly optimistic price targets due to business incentives, which can inflate expectations [8]

Group 1 - BioLife Solutions, Inc. (BLFS) shares have increased by 1.6% over the past four weeks, closing at $22.37, with a mean price target of $31.3 indicating a potential upside of 39.9% [1] - The average of 10 short-term price targets ranges from $30.00 to $34.00, with a standard deviation of $1.42, suggesting a potential increase of 34.1% to 52% from the current price level [2] - Analysts show strong agreement in revising earnings estimates higher, which correlates with potential stock price increases, as indicated by a 150% increase in the Zacks Consensus Estimate for the current year [11][12] Group 2 - BLFS holds a Zacks Rank 1 (Strong Buy), placing it in the top 5% of over 4,000 ranked stocks based on earnings estimates, indicating strong potential for upside [13] - While consensus price targets may not be reliable for predicting exact price movements, they can provide a directional guide for potential stock performance [14]